Treatment of breast cancer stem cells with oncolytic herpes simplex virus

DSpace/Manakin Repository

Treatment of breast cancer stem cells with oncolytic herpes simplex virus

Citable link to this page

 

 
Title: Treatment of breast cancer stem cells with oncolytic herpes simplex virus
Author: Hu, P; Li, J.; Zeng, W.; Zhang, Q.; Rabkin, Samuel David; Liu, R.

Note: Order does not necessarily reflect citation order of authors.

Citation: Li, J, W Zeng, Y Huang, Q Zhang, P Hu, S D Rabkin, and R Liu. 2012. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Therapy 19(10): 707-714.
Full Text & Related Files:
Abstract: Cancer stem cells have recently been isolated from several different solid tumors. In breast cancer, the \(CD44^{+} CD24^{−/low}\) population is considered to comprise stem-like cells. The identification of cancer stem cells has provided new targets for the development of therapeutics. Oncolytic herpes simplex viruses (oHSVs) are an effective strategy for killing breast cancer cells and treating breast tumors in preclinical models. Here, we examined the efficacy of the oHSV G47Δ in killing breast cancer stem cells. Human breast cancer cell line SK-BR-3 and human primary breast cancer cells were cultured in suspension under conditions conducive to the growth of stem cells. They generated mammospheres, which had cancer stem cell properties. The proportion of \(CD44^{+} CD24^{−/low}\) cells in these mammospheres exceeded 95%, as determined by flow cytometry. The mammospheres were found to be highly tumorigenic when implanted subcutaneously in nude BALB/c mice. G47Δ contains the LacZ gene, and X-gal staining of infected cells in vitro and in vivo showed the replication and spread of the virus. G47Δ was found to be highly cytotoxic to the \(CD44^{+} CD24^{−/low}\) population in vitro, even when injected at low multiplicities of infection, and G47Δ treatment in vivo significantly inhibited tumor growth compared with mock treatment. This study demonstrates that oHSV is effective against breast cancer stem cells and could be a beneficial strategy for treating breast cancer patients.
Published Version: doi:10.1038/cgt.2012.49
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444761/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10459030
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters